Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03209700 · ClinicalTrials.gov registry record · Phase 1
Re-treatment From a Phase I Study of MSC-AFP in Patients With Perianal Fistulas
A Phase 1 study, sponsored by William A. Faubion, M.D..
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT03209700: Completed Phase 1 study, sponsored by William A. Faubion, M.D..
NCT03209700 is a Phase 1 study that has completed, run by William A. Faubion, M.D.. The registered enrollment target is 7 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03209700, a Phase 1 study, has completed, sponsored by William A. Faubion, M.D..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This study is an extension to re-treat partial and non-responders from the previously approved Phase 1 MCS-AFP protocols IRB #12-009716 (Crohn's Disease perianal fistulas) and 15-003200 (cryptoglandular perianal fistulas).
Primary Outcome
Participants will have a health assessment and blood work measured at each study visit to monitor for adverse events, such as worsening of the perinal fistulizing disease, abnormal laboratory values, or significant abnormalities in physical examination. The Outcome Measure will be the number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment
Interventions
- DRUG MSC-AFP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2017-07-20 |
| Est. Completion | 2019-12-10 |
| Phase | Phase 1 |
What the finished NCT03209700 record still lists
NCT03209700 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 1 intervention - of which MSC-AFP is the first listed.
NCT03209700 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03209700 about?
NCT03209700 is a clinical study titled "Re-treatment From a Phase I Study of MSC-AFP in Patients With Perianal Fistulas". This study is an extension to re-treat partial and non-responders from the previously approved Phase 1 MCS-AFP protocols IRB #12-009716 (Crohn's Disease perianal fistulas) and 15-003200 (cryptoglandular perianal fistulas).
What is the current status of trial NCT03209700?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2017-07-20. Estimated completion is 2019-12-10.
What interventions are being tested in trial NCT03209700?
The interventions under investigation include: MSC-AFP (DRUG).
Who is sponsoring clinical trial NCT03209700?
This trial is sponsored by William A. Faubion, M.D., which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03209700's enrollment target sits among peer trials
7 1972nd of 2000 higher than 27 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI